MedPath

FDA Limits GSK's Xevudy Authorization Due to BA.2 Variant Concerns

The FDA has restricted the emergency use authorization of GSK and Vir's COVID-19 antibody therapy Xevudy (sotrovimab) in several U.S. regions due to reduced efficacy against the BA.2 Omicron subvariant. The companies are developing a higher dose formulation to address the BA.2 variant while continuing plans for full regulatory approval.

The U.S. Food and Drug Administration has scaled back the emergency use authorization (EUA) for GlaxoSmithKline and Vir Biotechnology's COVID-19 antibody therapy Xevudy (sotrovimab), citing new data indicating reduced effectiveness against the emerging BA.2 Omicron subvariant.
The regulatory restriction applies specifically to Health and Human Services (HHS) regions where BA.2 is becoming the dominant SARS-CoV-2 strain. Currently, the limitations affect region 1 (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont) and region 2 (New Jersey, New York, Puerto Rico, and the Virgin Islands).

Impact on Treatment Guidelines

The development marks another setback in the COVID-19 antibody therapy landscape. Earlier, the FDA had withdrawn authorization for Eli Lilly's bamlanivimab/etesevimab combination and Regeneron's REGEN-COV when data showed their diminished efficacy against the original BA.1 Omicron variant.
Current National Institutes of Health (NIH) treatment guidelines prioritize COVID-19 therapeutics in the following order:
  • Pfizer's Paxlovid (nirmatrelvir/ritonavir)
  • GSK/Vir's Xevudy
  • Gilead's Veklury (remdesivir)
  • Merck & Co/Ridgeback Bio's Lagevrio (molnupiravir)

Clinical Efficacy and Commercial Impact

Xevudy initially received its EUA in May 2021 based on impressive phase 3 results, demonstrating a 79% reduction in risk of hospitalization or death compared to placebo in patients with mild-to-moderate COVID-19. The therapy has since become a significant revenue generator for GSK, contributing approximately $1.25 billion to the company's 2021 revenues, with similar projections for 2022.
The U.S. government had previously committed around $1 billion for an estimated 750,000 doses of Xevudy.

Development of Higher Dose Formulation

GSK and Vir have responded proactively to the BA.2 challenge, announcing their work on a higher dose formulation of Xevudy. The companies believe this new formulation will effectively combat the BA.2 subvariant and plan to share supporting data with global regulatory authorities. Despite the current setback, they maintain their timeline for seeking full regulatory approval this year.

Emerging Alternative: AstraZeneca's Evusheld

As Xevudy faces challenges, AstraZeneca's Evusheld (tixagevimab/cilgavimab) has secured EU approval for pre-exposure prophylaxis of COVID-19. The long-acting antibody combination demonstrated 77% efficacy in preventing symptomatic COVID-19 compared to placebo in the PROVENT phase 3 trial, with protection lasting at least six months. Notably, Evusheld has shown retained neutralizing activity against the BA.2 variant.
Dr. Christoph Spinner from University Hospital Rechts der Isar in Germany emphasized the timing of this approval: "Increasing COVID-19 cases, driven by the highly-transmissible BA.2 subvariant, and withdrawal of several pandemic public health measures make it important to protect vulnerable populations, such as the immunocompromised, from SARS-CoV-2 infection."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Invivyd's Pemgarda Shows Continued Neutralizing Activity Against SARS-CoV-2 Variant XEC

Invivyd's PEMGARDA (pemivibart) demonstrates consistent neutralizing activity against the dominant SARS-CoV-2 variant XEC in new in vitro data.
XEC and KP.3.1.1, both susceptible to PEMGARDA, constitute the majority (69%) of circulating SARS-CoV-2 variants in the U.S., according to CDC estimates.

AZ's Antibody First to Be Cleared by FDA for COVID Prevention

AstraZeneca's antibody cocktail, Evusheld, has been authorized by the FDA for COVID-19 prevention in individuals with compromised immunity, marking a significant advancement in the fight against the pandemic.

FDA Rejects Astellas' Label Update for Geographic Atrophy Drug Izervay

The FDA issued a complete response letter for Astellas' Izervay label update, which included data from the Phase 3 GATHER2 trial, impacting its competitive positioning.
The FDA's rejection was based on a statistical matter related to the proposed labeling language, with no concerns raised regarding the drug's safety or efficacy data.

FDA Revokes Authorization of GSK and Vir's Sotrovimab Due to BA.2 Inefficacy

The FDA has fully revoked the emergency use authorization for GlaxoSmithKline and Vir Biotechnology's sotrovimab due to its reduced efficacy against the Omicron sub-variant BA.2.
Sotrovimab initially received EUA based on Phase III trial data showing an 85% reduction in hospitalization or death risk for high-risk COVID-19 patients.

FDA Rejects Vanda Pharmaceuticals' Fanapt for Gastroparesis

The FDA has declined to approve Vanda Pharmaceuticals' supplemental New Drug Application (sNDA) for Fanapt (iloperidone) in treating gastroparesis, a stomach condition characterized by delayed gastric emptying.
This rejection marks a setback for Vanda, which sought to expand Fanapt's indication beyond its current approval for schizophrenia, addressing an unmet need in gastroparesis management.

FDA Updates Pemgarda EUA Due to Emerging SARS-CoV-2 Variants

The FDA has revised the Emergency Use Authorization for Pemgarda, limiting its use to situations where variants with reduced susceptibility are 90% or less of circulating strains.
This decision follows data indicating some SARS-CoV-2 variants, like KP.3.1.1, may exhibit substantially reduced susceptibility to Pemgarda.

FDA Revokes Emergency Use Authorization for Evusheld Due to Variant Ineffectiveness

The FDA has revoked the emergency use authorization for Evusheld (tixagevimab/cilgavimab) in the U.S. due to its reduced efficacy against emerging SARS-CoV-2 variants.
Recent data indicates that Evusheld is unlikely to be effective against current dominant variants, such as XBB.1.5, which account for the majority of new infections.

FDA Warns Evusheld May Be Ineffective Against COVID-19 Subvariant XBB.1.5

The FDA has cautioned that Evusheld, a preexposure prophylaxis for COVID-19, may not neutralize the XBB.1.5 subvariant, which accounts for nearly 30% of cases.
The agency is awaiting further data but suggests that Evusheld's effectiveness is compromised against XBB.1.5 compared to other variants.

FDA Restricts Emergency Use Authorization for AstraZeneca's Evusheld in the US

The FDA has restricted the emergency use authorization for AstraZeneca's Evusheld in the US due to the prevalence of resistant SARS-CoV-2 variants.
Evusheld is not currently authorized for pre-exposure prophylaxis of COVID-19 in the US until the prevalence of resistant variants decreases.

FDA Restricts Sotrovimab Use Due to Omicron BA.2 Variant Resistance

The FDA has suspended the authorization of GlaxoSmithKline and Vir Biotechnology's sotrovimab in regions where the Omicron BA.2 subvariant is dominant, citing inefficacy.
Sotrovimab, a monoclonal antibody, was previously authorized for treating high-risk COVID-19 patients but shows reduced effectiveness against the BA.2 subvariant.

Reference News

[1]
FDA restricts GSK's Xevudy due to lower efficacy against BA.2
pharmaphorum.com · Jan 24, 2025

FDA restricts Xevudy's use due to inefficacy against Omicron's BA.2 subvariant in certain regions. GSK and Vir are devel...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy